CSL Share Price Update: Buy‑Back Acceleration and US$1.5 Billion US Expansion Shape Outlook on 21 November 2025
MELBOURNE / SYDNEY – 21 November 2025 – CSL Limited (ASX: CSL), the Australian biopharmaceutical giant and long‑time ASX 20 heavyweight, entered Friday’s trade with two dominant storylines: a fresh on‑market share buy‑back update lodged with the ASX this morning, and the market’s ongoing reaction to its recently announced US$1.5 billion investment program in US plasma‑derived therapy manufacturing. Global Newsroom | CSL+3Australian Securities Exchange+3AFR Company Announcements+3 At the same time, the CSL share price remains deep in recovery mode after a brutal year. External research estimates the stock is down roughly 36% year to date, turning what was once a market darling into